Kalehua Capital Management LLC
13F Reported Value
ⓘ$139.5M
Holdings
23
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Kalehua Capital Management LLC disclosed 23 positions worth $139.5M in its Form 13F-HR for Q2 2026, led by $MANE (Veradermics, Inc) at 12.8% of the equity portfolio, followed by $XFOR and $CMPS. During the quarter the fund opened 7 new positions and exited 7 — including a new stake in $KPTI. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Kalehua Capital Management LLC’s Form 13F-HR filing with the SEC under CIK 2106181.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$17.9M145,695 sh - 28.0#2,572
Quality
$17.4M3,722,840 sh - —
Quality
$11.6M819,692 sh - —
Quality
$10.0M385,178 sh - 12.0
Quality
$9.7M1,832,365 sh - —
Quality
$8.7M197,072 sh - —
Quality
$7.8M3,821,890 sh - —
Quality
$6.9M198,772 sh - 15.1
Quality
$6.7M685,644 sh - 59.2
Quality
$6.5M194,544 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Veradermics, Inc$MANE | — | $17.9M | 145,695 |
 X4 Pharmaceuticals, Inc$XFOR | 28.0#2,572 | $17.4M | 3,722,840 |
 COMPASS Pathways plc$CMPS | — | $11.6M | 819,692 |
 Surrozen, Inc./DE$SRZN | — | $10.0M | 385,178 |
 Aclaris Therapeutics, Inc.$ACRS | 12.0 | $9.7M | 1,832,365 |
 Sionna Therapeutics, Inc.$SION | — | $8.7M | 197,072 |
 Inhibikase Therapeutics, Inc.$IKT | — | $7.8M | 3,821,890 |
 Pharvaris N.V.$PHVS | — | $6.9M | 198,772 |
 Karyopharm Therapeutics Inc.$KPTI | 15.1 | $6.7M | 685,644 |
 Septerna, Inc.$SEPN | 59.2 | $6.5M | 194,544 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Kalehua Capital Management LLC's 23 positions.
Showing top 10 of 23 holdings.
Sector Allocation
Healthcare
$139.5M
Full Holdings — Kalehua Capital Management LLC (Q2 2026)
All 23 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $MANE | Veradermics, Inc | $17.9M | 12.8% | +42% | — |
| 2 | $XFOR | X4 Pharmaceuticals, Inc | $17.4M | 12.5% | +0% | 28 |
| 3 | $CMPS | COMPASS Pathways plc | $11.6M | 8.3% | +0% | — |
| 4 | $SRZN | Surrozen, Inc./DE | $10.0M | 7.2% | +0% | — |
| 5 | $ACRS | Aclaris Therapeutics, Inc. | $9.7M | 7.0% | +37% | 12 |
| 6 | $SION | Sionna Therapeutics, Inc. | $8.7M | 6.2% | +0% | — |
| 7 | $IKT | Inhibikase Therapeutics, Inc. | $7.8M | 5.6% | +43% | — |
| 8 | $PHVS | Pharvaris N.V. | $6.9M | 4.9% | +0% | — |
| 9 | $KPTI | Karyopharm Therapeutics Inc. | $6.7M | 4.8% | NEW | 15.1 |
| 10 | $SEPN | Septerna, Inc. | $6.5M | 4.7% | +0% | 59.2 |
| 11 |  $IFRX | InflaRx N.V. | $6.5M | 4.7% | NEW | — |
| 12 |  $CYCN | Cyclerion Therapeutics, Inc. | $5.6M | 4.0% | NEW | — |
| 13 |  $QURE | uniQure N.V. | $3.7M | 2.6% | -62% | — |
| 14 |  $LONA | LeonaBio, Inc. | $3.6M | 2.6% | +0% | — |
| 15 |  $DMRA | Damora Therapeutics, Inc. | $3.6M | 2.6% | +0% | — |
| 16 |  $MLTX | MoonLake Immunotherapeutics | $3.4M | 2.5% | +0% | — |
| 17 |  $TYRA | Tyra Biosciences, Inc. | $2.4M | 1.7% | +0% | — |
| 18 |  $NVCT | Nuvectis Pharma, Inc. | $1.8M | 1.3% | NEW | — |
| 19 |  $GOSS | Gossamer Bio, Inc. | $1.8M | 1.3% | +49% | 8.2 |
| 20 |  $MIST | Milestone Pharmaceuticals Inc. | $1.7M | 1.2% | NEW | — |
| 21 |  $ATYR | aTYR PHARMA INC | $1.1M | 0.8% | NEW | — |
| 22 |  $TIL | Instil Bio, Inc. | $765,924 | 0.6% | -29% | 30 |
| 23 |  $TCRX | TScan Therapeutics, Inc. | $445,824 | 0.3% | NEW | 13.9 |
New Positions (7)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Kalehua Capital Management LLC including:
Track Kalehua Capital Management LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Kalehua Capital Management LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Kalehua Capital Management LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Kalehua Capital Management LLC (SEC CIK: 2106181), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Kalehua Capital Management LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.